-
Teva’s Ajovy Achieves Positive Results in Phase III Migraine Prevention Trial in China
•
Teva Pharmaceutical Industries Ltd (NYSE: TEVA), headquartered in Israel, has announced positive results from a Phase III study for Ajovy (fremanezumab) as a preventive treatment for migraine in adult Chinese patients. The study met its primary and all secondary endpoints, demonstrating Ajovy’s efficacy in reducing the number of migraine days…
-
LargeV Instrument’s IPO on STAR Board Halted Following Filing and Sponsorship Withdrawal
•
The initial public offering (IPO) of LargeV Instrument Corp., Ltd to the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR) has been suspended for review, following the withdrawal of the filing and sponsorship. The Beijing-based company, which specializes in the research and development (R&D), manufacturing, and marketing of medical cone-shaped beam…
-
Enhertu Shows 58.3% Response Rate in Phase II Lung Cancer Study, AstraZeneca and Daiichi Sankyo Report
•
The Phase II DESTINY-Lung05 study results for Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate co-developed by AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568, OTCMKTS: DSNKY), were unveiled at the American Association for Cancer Research (AACR) 2024 annual meeting. The study reported an objective response rate (ORR) of 58.3% (95% CI:…
-
Yantai Dongcheng Secures Approval for Phase I Study of 68Ga-LNC1007 in Singapor
•
Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) has received approval from the Health Sciences Authority of Singapore to initiate a Phase I clinical study for its radiopharmaceutical candidate, 68Ga-LNC1007. This diagnostic agent targets fibroblast activating protein (FAP) and integrin αvβ3, and is being developed to aid in the treatment…
-
Sino Biopharmaceutical to Present Phase II Data for Garsorasib at AACR 2024
•
Sino Biopharmaceutical Ltd. (HKG: 1177) announced that it will present the results of a Phase II study for garsorasib (D-1553), a KRAS G12C inhibitor co-developed with InventisBio (Shanghai) Co., Ltd., at the American Association for Cancer Research (AACR) 2024 annual meeting. The study focuses on non-small cell lung cancer (NSCLC)…
-
STRATA Skin Sciences Renews Exclusive Distribution Deals in China and Japan
•
STRATA Skin Sciences Inc. (NASDAQ: SSKN), a U.S.-based dermatology and plastic surgery firm, has announced the renewal of exclusive distribution agreements with its two partners for the China and Japan markets. Each agreement spans three years and includes minimum unit placements and purchases for STRATA’s XTRAC and VTRAC devices. The…
-
Aptar Pharma Secures NMPA Approval for Airless Drug Delivery System in Chin
•
Aptar Pharma, a U.S.-based company, announced that its Mezzo+ CS (China Support) Airless dispensing solution has received market approval in China. This innovative system is designed for dermal drug delivery and will be utilized for Sinomune Pharmaceutical’s metronidazole gel, which has been approved by the National Medical Products Administration (NMPA)…
-
BIO’s Chief Lobbyist Nick Shipley Resigns Amid Controversy Over WuXi AppTec
•
Nick Shipley, the chief lobbyist for the U.S.-based Biotechnology Innovation Organization (BIO), has resigned from his position, as first reported by Endpoints News and confirmed by FiercePharma. Shipley, who joined BIO in 2021 as chief advocacy officer, was responsible for the organization’s interactions with federal and state governments. He departed…
